NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma Closes $26 Million Financing, Expands Development of Novel Immuno-Oncology Products
SAN FRANCISCO, Dec. 11, 2013 - Sutro Biopharma today announced that the company has secured $26 million in a Series D financing. The additional financing will fund the expansion of Sutro’s proprietary immuno-oncology product pipeline. Sutro is developing a new...
World ADC Summit 2013 – Dual-Warhead Antibody Drug Conjugate
SAN FRANCISCO, Oct. 15, 2013 - Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro's cell-free protein synthesis technology, presented today the first data involving a dual-warhead antibody drug conjugate...
Producing Homogeneous ADCs with Combination Warheads
Hallam, Trevor, Producing Homogeneous ADCs with Combination Warheads Presented at the 4th World ADC Summit, San Francisco (PDF) Read More
Antibody-Drug Conjugates and Cancer Treatment: Making “Smart Bombs” Smarter
Scientific American Guest Blog Antibody-Drug Conjugates and Cancer Treatment: Making "Smart Bombs" Smarter By: Trevor J. Hallam Read More
Cell-Free Translation of Peptides and Proteins: From High Throughput Screening to Clinical Production
Christopher J Murray, and Ramesh Baliga, Cell-free translation of peptides and proteins: from high throughput screening to clinical production, Current Opinion in Chemical Biology 2013, 17:420–426, PDF Read More
Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer
SAN FRANCISCO, Jan. 31, 2013 - Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro's cell-free protein synthesis technology, today announced the expansion of its senior management team with the appointment...
Sutro Biopharma to Collaborate with Sanofi Pasteur on a Novel Production Approach for Vaccine Candidates
SAN FRANCISCO, Jan. 3, 2013 - Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro's cell-free protein synthesis technology, today announced a collaboration with Sanofi Pasteur -- the largest company entirely...
Sutro Biopharma Collaborates with Celgene Corporation to Design and Develop Next-Generation Antibody Drug Conjugates and Bispecific Antibodies
SAN FRANCISCO, Dec. 18, 2012 - Sutro Biopharma today announced a collaboration with Celgene Corporation to design and develop novel antibody drug conjugates (ADCs) and bispecific antibodies for two undisclosed targets and to manufacture a proprietary Celgene antibody....
Sutro Biopharma Expands Senior Management Team Jeremy Bender, Ph.D., Joins as Chief Business Officer; Aaron K. Sato, Ph.D., Named Vice President, Research
SAN FRANCISCO, October 24, 2012 - Sutro Biopharma, a biopharmaceutical company developing a new generation of antibody drug conjugate therapeutics and bifunctional antibody-based therapeutics for targeted cancer therapies, today announced the expansion of its senior...
Rapid Design and Manufacture of Single Species, Site-Specific ADCs using Cell-Free Synthesis with nnAAs
Hallam, Trevor, Rapid Design and Manufacture of Single Species, Site-Specific ADCs using Cell-Free Synthesis with nnAAs. Presented at the 3rd World ADC Summit, San Francisco (PDF) Read More